Project Details
Description
An open-label Phase II trial to investigate the efficacy, safety, and pharmacokinetics of a single dose of 200 mg i.v. BI 2536 BS administered every 21 days in patients w
| Status | Finished |
|---|---|
| Effective start/end date | 8/15/07 → 8/15/08 |
Funding
- BOEHRINGER-INGELHEIM PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.